<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387295</url>
  </required_header>
  <id_info>
    <org_study_id>MA 0918</org_study_id>
    <nct_id>NCT01387295</nct_id>
  </id_info>
  <brief_title>Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease</brief_title>
  <official_title>Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorte Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second&#xD;
      week in combination with systemic capecitabine and in patients with a HER2-positive tumour in&#xD;
      combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases&#xD;
      from breast cancer.&#xD;
&#xD;
      Only patients with limited extrahepatic disease are included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months after last patient included</time_frame>
    <description>Number of patients with complete or partial response in the liver (RECIST version 1.1). Only patients with measurable disease are included in the protocol. Response rate number of patients with CR + PR divided with total number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients suitable for local therapy (radiofrequency)</measure>
    <time_frame>6 months after last patient included</time_frame>
    <description>Total number of patients receiving RF treatment or surgical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months after last patient included</time_frame>
    <description>All patients in intent-to-treat population , calculated from start of treatment to death of any course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>28 days after last treatment of last patient</time_frame>
    <description>All patients who received at least one dose of study drug are evaluable for toxicity. CTC version 3.0 will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months after last patient included</time_frame>
    <description>From start of therapy to progression or death of any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin, capecitabine, trastuzumab</intervention_name>
    <description>Oxaliplatin intrahepatic capecitabine and trastuzumab systemic</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>HAI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• Informed consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Performance status 0-1; expected survival ≥ 3 months&#xD;
&#xD;
          -  Patient with histologically or cytologically confirmed locally advanced or metastatic&#xD;
             adenocarcinoma of the breast&#xD;
&#xD;
          -  Liver metastases not suitable for local treatment&#xD;
&#xD;
          -  Extrahepatic disease should be determined by PET-CT-scan.&#xD;
&#xD;
          -  No progression on treatment with capecitabine.&#xD;
&#xD;
          -  Prior treatment with taxane (adjuvant or for metastatic disease)&#xD;
&#xD;
          -  Metastases &lt; 70 % of the liver&#xD;
&#xD;
          -  Neutrophile granulocytes &gt; 1.5 x 109/l og thrombocytes &gt; 100 x 109/l&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 x UNL (upper normal limit).&#xD;
&#xD;
          -  Creatinine-clearance &gt; 30 ml/min.&#xD;
&#xD;
          -  INR &lt; 1.6.&#xD;
&#xD;
          -  If the patient is HER2-positive:Baseline LVEF ≥ 50 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chemotherapy within the 4-week period prior to the start of trial&#xD;
             medication&#xD;
&#xD;
          -  Other current or prior malignant disease except adequately treated and cured carcinoma&#xD;
             in situ of the cervix or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Previous treatment with oxaliplatin&#xD;
&#xD;
          -  Cytotoxic or experimental treatment within a 14 days period before start of trial&#xD;
             medication&#xD;
&#xD;
          -  The patient is not allowed to participate in other clinical trials.&#xD;
&#xD;
          -  Any clinical symptoms suggesting peripheral neuropathy &lt; or equal to grade 2 or CNS&#xD;
             metastases (In case of clinical suspicion on CNS metastases a MR or CT scan should be&#xD;
             performed within 4 weeks before inclusion&#xD;
&#xD;
          -  Other severe medical conditions e.g. severe cardial disease or AMI &lt; 1 year&#xD;
&#xD;
          -  Presence of diseases which prevent oral therapy.&#xD;
&#xD;
          -  Patients with uncontrolled infection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women capable of childbearing not using a sufficient non-hormonal method of birth&#xD;
             control&#xD;
&#xD;
          -  Patients not able to understand the treatment or to collaborate.&#xD;
&#xD;
          -  Prior serious or unsuspected reaction after treatment with fluoropyrimidine&#xD;
&#xD;
          -  Known prior hypersensitivity reactions to the agents&#xD;
&#xD;
        If the patient is HER2-positive:&#xD;
&#xD;
          -  Dyspnoea in due to complication related to malignant disease e.g.lung metastases with&#xD;
             lymphangitis or other conditions with need of supportive oxygen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorte Nielsen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorte Nielsen, Professor</last_name>
    <phone>+4544884000</phone>
    <phone_ext>82344</phone_ext>
    <email>dornie01@heh.regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birgitte Krogh Jensen, Study nurse</last_name>
    <phone>+4544884000</phone>
    <phone_ext>89562</phone_ext>
    <email>bikrje01@heh.regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorte Nielsen, Professor</last_name>
      <phone>+4544884000</phone>
      <phone_ext>82344</phone_ext>
      <email>dornie01@heh.regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Birgitte Krogh Jensen, Study nurse</last_name>
      <phone>+454488000</phone>
      <phone_ext>89562</phone_ext>
      <email>bikrje01@heh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Dorte Nielsen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dorte Nielsen</investigator_full_name>
    <investigator_title>Responsible Party was entered in the old format as Dorte Nielsen, professor DMSci, Department of Oncology, Herlev Hospital.</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>intrahepatic chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 1, 2020</submitted>
    <returned>October 23, 2020</returned>
    <submitted>October 19, 2021</submitted>
    <returned>November 16, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

